GeoPolitics Pulse

The Heartbeat of World events

WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications

by ·

February 18, 2025 6:45 am ET. WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union.Read More

Related posts:

  1. European Commission Approves Belzutifan for VHL Disease–Associated Tumors, Advanced ccRCC
  2. Calliditas partner STADA receives European Commission decision for full approval of … – KXAN
  3. TEPKINLY® (epcoritamab) Receives Second European Commission Approval for … – Business Wire
  4. AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab …
  5. InflaRx Receives European Commission Approval for GOHIBIC® – GlobeNewswire